Nectar Lifesciences Ltd. shares fell nearly 20% to ?18.60 after announcing the sale of its API and formulations business to Ceph Lifesciences for ?1,270 crore. The deal aims to streamline operations and unlock shareholder value while the stock remains down over 26% in the past year.